

PATENT Customer No. 22,852 Attorney Docket No. **09605.0011**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Vittorio DAL PIAZ et al.) Oroup Art Unit: Not Yet Assigned O
Application No.: 10/539,821) Examiner: Not Yet Assigned
Filed: June 20, 2005	Confirmation No.: 5918
For: NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES)))
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

U.S. Application No.: 10/539,821

Attorney Docket No. 09605.0011

Applicants enclose the International Search Report for WO 2004/058729, which

is the PCT counterpart of the present application and the Spanish Search Report for

P200203003, from which the present application claims priority.

This submission does not represent that a search has been made or that no

better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and applicants determine

that the cited documents do not constitute "prior art" under United States law, applicants

reserve the right to present to the office the relevant facts and law regarding the

appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the

patentability of the disclosed invention over the listed documents, should one or more of

the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please

charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

Carlos M. Tellez

Reg. No. 48,638

Dated: December 14, 2005

- 2 -

IDS.	Form	PTO/SR/08	Substitute	for form	144QA/PTC

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of 1

Complete if Known			
Application Number 10/539,821			
Filing Date	June 20, 2005		
First Named Inventor	Vittorio DAL PIAZ		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	09605.0011		

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS						
	Cite	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
	No.¹	No. ¹ Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear		
	1	US-5,859,008	12 JAN 1999	Jonas et al.			
		US-					
		US-					
		US-					

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	2	WO 93/07146	15 APR 1993			
	3	WO 03/097613	27 NOV 2003			
	4	WO 2005/049581	02 JUN 2005			
				<u> </u>		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶			
	5	Daniela BARLOCCO, et al., "Phenylpiperazinylalkylamino Substituted Pyridazinones as Potent α ₁ Adrenoceptor Antagonists, J. Med., Chem., 44:2403-2410 (2001).				
	6	Giovanna CICIANI, et al., "Synthesis and Evaluation of In Vitro Antitumor Activity of Some Substituted 5- Pyridazinyl-Styrylketones," Il Farmaco, 46 (7,8)873-885 (1991).				
	7	Luca COSTANTINO, et al., "Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a Potential Substrate for New Aldose Reductase Inhibitors," J. Med. Chem., 42:1894-1900 (1999).				
	8	Vittorio DAL PIAZ, et al., "5-Acyl-6-aryl-4-nitro-3(2H)pyridazinones and Related 4-Amino Compounds: Synthesis and Pharmacological Evaluation," Journal of Pharmaceutical Sciences, 80(4):341-348 (1991).				
	9	Vittorio DAL PIAZ, et al., "4,5-Functionalized 6-phenyl-3(2H)-pyridazinones: synthesis and evaluation of antinociceptive activity," Eur. J. Med. Chem., 31:65-70 (1996).				
	10	International Search Report for WO 2004/058729 dated March 10, 2004	""			
	11	Spanish Search Report for P 200203003 dated May 17, 2004				

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.